<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04132323</url>
  </required_header>
  <id_info>
    <org_study_id>A001203</org_study_id>
    <nct_id>NCT04132323</nct_id>
  </id_info>
  <brief_title>Low Concentrate Detergents Versus Hypertonic Glucose for the Treatment of Telangiectasia</brief_title>
  <official_title>Clinical Efficacy of Low Concentrate Detergents Versus Hypertonic Glucose for the Treatment of Telangiectasia: a Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derzhavin Tambov State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Derzhavin Tambov State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using of low concentrate sodium tetradecyl sulfate for sclerotherapy of telangiectasias
      should be no less effective than hypertonic glucose, and have a comparable frequency of
      adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For sclerotherapy of telangiectasias are used detergents. These are aggressive substances,
      which have a high frequency of adverse events. According to histological studies the safest
      concentration for the treatment of telangiectasias is less than that specified in the
      official instructions. The concentration of sodium tetradecyl sulfate 0.15% was effective and
      did not cause any adverse reactions in the treatment of telangiectasias from 0.8 to 1 mm in
      diameter. Small telangiectases (0.5 mm or less) require the treatment with the less
      aggressive sclerosing agent. Perhaps, the sodium tetradecyl sulfate 0.15%, 0.1% or even 0.05%
      and hypertonic glucose may be more effective and safe in this situation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disappearance of the telangiectasia</measure>
    <time_frame>2 months</time_frame>
    <description>The clearing of the vessels on the six-point scale (from 0 to 5 points): 5 - total disappearance of the matting (100% efficacy), 4 - disappearance of around 80%, 3 - disappearance of around 60%, 2 - disappearance of around 40%, 1 - disappearance of around 20%, 0 - no changes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain during the procedure: visual analog scale</measure>
    <time_frame>immediately after the procedure</time_frame>
    <description>Estimate of the pain on visual analog scale. Visual analog scale [VAS] is a measure of pain intensity. It is a continuous scale comprised of a horizontal 10 cm length: &quot;no pain&quot; (score of 0) and &quot;pain as bad as it could be&quot; or &quot;worst imaginable pain&quot; (score of 10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction After Treatment</measure>
    <time_frame>2 months</time_frame>
    <description>Assessment of patient satisfaction on the 3-point scale :
no result (0 points),
incomplete satisfaction (1 point),
complete satisfaction (2 points)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Sclerotherapy</condition>
  <arm_group>
    <arm_group_label>hypertonic glucose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.
to measure the maximum diameter of telangiectasia using the Dermatoscope scale.
to inject the 75% glucose, with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.05% sodium tetradecyl sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.
to measure the maximum diameter of telangiectasia using the Dermatoscope scale.
to inject the 0.05% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% sodium tetradecyl sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.
to measure the maximum diameter of telangiectasia using the Dermatoscope scale.
to inject the 0.1% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.15% sodium tetradecyl sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.
to measure the maximum diameter of telangiectasia using the Dermatoscope scale.
to inject the 0.15% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sclerotherapy</intervention_name>
    <description>Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group</description>
    <arm_group_label>0.05% sodium tetradecyl sulfate</arm_group_label>
    <arm_group_label>0.1% sodium tetradecyl sulfate</arm_group_label>
    <arm_group_label>0.15% sodium tetradecyl sulfate</arm_group_label>
    <arm_group_label>hypertonic glucose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women over 18

          -  single primary or secondary telangiectasias unrelated to the reticular veins

          -  signed informed consent to participate in the study

        Exclusion Criteria:

          -  telangiectasias associated with reticular veins

          -  diabetes mellitus

          -  pregnancy or lactation

          -  malignant neoplasms

          -  inability or unwillingness of the patient to wear compression stockings

          -  hypersensitivity to one of the drugs

          -  concomitant diseases: bronchial asthma, severe liver and kidney disease, acute
             thrombosis and thrombophlebitis, infection of the skin and/or soft tissues, infectious
             diseases, arteriosclerosis, diabetic angiopathy, heart defects requiring surgery,
             fever, toxic hyperthyroidism, obesity, tuberculosis, sepsis, violation of the cellular
             composition of the blood, all diseases requiring bed rest, heart disease with
             decompensation phenomena, known hereditary thrombophilia.

          -  period after treatment of alcoholism

          -  reception of oral contraceptives

          -  sedentary lifestyle
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oksana Bukina, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Derzhavin Tambov State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oksana V Bukina, PhD</last_name>
    <phone>+79051204983</phone>
    <email>ovsafonova@yandex.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander A Sinitsyn</last_name>
    <phone>+79202670286</phone>
    <email>dr.sinicin@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bukina Oksana Vasilyevna</name>
      <address>
        <city>Tambov</city>
        <zip>392014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oksana V Bukina, PhD</last_name>
      <phone>+79051204983</phone>
      <email>ovsafonova@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Esadulla A Osmanov, Professor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandr A Sinitsyn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrey V Pelevin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oksana I Efremova, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vladimir E Denisov, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalia U Kondratiuk</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <results_reference>
    <citation>Bush R, Bush P. Evaluation of sodium tetradecyl sulfate and polidocanol as sclerosants for leg telangiectasia based on histological evaluation with clinical correlation. Phlebology. 2017 Aug;32(7):496-500. doi: 10.1177/0268355516673768. Epub 2016 Oct 12.</citation>
    <PMID>27738241</PMID>
  </results_reference>
  <results_reference>
    <citation>Rabe E, Schliephake D, Otto J, Breu FX, Pannier F. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology. 2010 Jun;25(3):124-31. doi: 10.1258/phleb.2009.009043.</citation>
    <PMID>20483861</PMID>
  </results_reference>
  <results_reference>
    <citation>Parlar B, Blazek C, Cazzaniga S, Naldi L, Kloetgen HW, Borradori L, Buettiker U. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):549-54. doi: 10.1111/jdv.12627. Epub 2014 Jul 28.</citation>
    <PMID>25069999</PMID>
  </results_reference>
  <results_reference>
    <citation>Munia MA, Wolosker N, Munia CG, Chao WS, Puech-Le√£o P. Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatol Surg. 2012 Apr;38(4):635-9. doi: 10.1111/j.1524-4725.2011.02226.x. Epub 2011 Dec 30.</citation>
    <PMID>22221551</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Derzhavin Tambov State University</investigator_affiliation>
    <investigator_full_name>Oksana Bukina</investigator_full_name>
    <investigator_title>Director, Clinical Research</investigator_title>
  </responsible_party>
  <keyword>sclerotherapy, hypertonic glucose, sodium tetradecyl sulfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study data are available to all investigators in the chronic vein disease registry.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>From 25 October 2019 to 25 December 2021</ipd_time_frame>
    <ipd_url>https://www.venousregistry.org/index.php?u=1</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.venousregistry.org/index.php?f=1&amp;id=97</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

